New study monitors infection risks in blood cancer patients on bispecific antibodies
NCT ID NCT07609576
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. Researchers will track how often infections occur, how severe they are, and what factors raise infection risk. The goal is to better understand and manage these complications, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIESPECIFIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Infanta Leonor University Hospital
RECRUITINGMadrid, Madrid, 28041, Spain
-
University Hospital Infanta Leonor
RECRUITINGMadrid, Madrid, 28005, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a new drug combo outsmart resistant myeloma?